Argenx stock holds gains as Vyvgart growth drives higher 2024 guidance
Published on 07/26/2026 at 14:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Argenx stock is underpinned by stronger fundamentals after argenx SE (ISIN NL0010832176) lifted its 2024 revenue outlook on the back of accelerating Vyvgart sales and a narrowing loss in the first quarter of 2024, according to the companys latest published financial figures.
Revenue up 46 percent in 2023
According to the companys reported full year 2023 results, argenx generated total revenue of about $1.37 billion in 2023, an increase of roughly 46 percent compared with approximately $939 million in 2022, driven primarily by uptake of its FcRn inhibitor efgartigimod marketed as Vyvgart in generalized myasthenia gravis and other indications.
The same 2023 report shows that argenx recorded a net loss of around $306 million for 2023, an improvement from a net loss of about $384 million in 2022 as higher gross profit from Vyvgart helped to offset increased research and development spending and commercial investment.
Management also highlighted that operating expenses remained elevated as argenx continued to invest in a broad late stage pipeline including additional autoimmune indications for efgartigimod and other antibody candidates, reflecting the groups strategy to balance top line growth with long term portfolio expansion.
Vyvgart product sales exceed 1 billion dollars
In its full year 2023 disclosure, argenx reported that global net product sales of Vyvgart reached approximately $1.15 billion in 2023, more than double the roughly $400 million recorded in 2022, underscoring the speed at which the therapy has been adopted in its approved markets.
The companys quarterly breakdown indicates that Vyvgart sales in the fourth quarter of 2023 were on the order of $374 million, up strongly compared with about $123 million in the fourth quarter of 2022, illustrating both the impact of label expansions and the scaling of commercial infrastructure across regions.
Argenx has stated in its investor communications that it expects continued growth in Vyvgart sales as it pursues additional indications and geographic launches, which in turn supports the higher revenue guidance communicated for 2024 relative to the prior year.
Further details on argenx figures
For more detailed breakdowns of segment sales, pipeline progress and guidance updates, additional reports and disclosures are available in the argenx investor section and in regulatory filings.
Vyvgart drives autoimmune franchise
Vyvgart, based on the antibody fragment efgartigimod, is the lead commercial product in the argenx portfolio and is indicated for generalized myasthenia gravis, where it works by targeting the neonatal Fc receptor to reduce pathogenic immunoglobulin G antibodies that contribute to disease activity.
The companys disclosures show that Vyvgart revenue is diversified across intravenous and subcutaneous formulations and across multiple regions, with uptake in the United States, Europe, Japan and other geographies providing a broader base for potential future growth relative to the early launch phase.
Argenx stock and market positioning
Argenx stock is listed via argenx SEs primary listing on Euronext Brussels and is also represented by American Depositary Shares on Nasdaq, which has helped the company access both European and US capital markets as it funds the commercialization of Vyvgart and the advancement of its pipeline.
As of the most recently available market data from a leading financial portal, the company carried a multibillion dollar market capitalization, reflecting investor expectations for continued growth in Vyvgart sales and the potential value of additional indications for efgartigimod and other pipeline assets.
Argenx stock key data
- Company: argenx SE
- ISIN: NL0010832176
- Ticker: NASDAQ: ARGX
- Trading venue: Euronext Brussels / Nasdaq (ADS)
- Sector / Industry: Biotechnology / Biopharmaceuticals
- Index membership: BEL 20
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
